WallStreetZenWallStreetZen

NASDAQ: NAUT
NAUTILUS BIOTECHNOLOGY INC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for NAUT

Based on 3 analysts offering 12 month price targets for NAUTILUS BIOTECHNOLOGY INC.
Min Forecast
$8.00+107.79%
Avg Forecast
$10.33+168.39%
Max Forecast
$13.00+237.66%

Should I buy or sell NAUT stock?

Based on 4 analysts offering ratings for NAUTILUS BIOTECHNOLOGY INC.
Buy
Strong Buy
1 analysts 25%
Buy
1 analysts 25%
Hold
2 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

NAUT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Anonymous
Goldman Sachs
HoldMaintains$5.00+29.87%2022-04-13
Morgan Stanley
Bottom 10%
10
HoldInitiates Coverage On$8.00+107.79%2022-01-06
Cowen & Co.
Bottom 5%
5
BuyInitiates Coverage OnN/AN/A2021-11-02
Goldman Sachs
Bottom 1%
1
HoldInitiates Coverage On$10.00+159.74%2021-08-04
Jefferies
Top 12%
89
Strong BuyInitiates Coverage On$13.00+237.66%2021-07-13

1 of 1

Forecast return on equity

Is NAUT forecast to generate an efficient return?
Company
-20.29%
Industry
124.21%
Market
32.71%
NAUT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NAUT forecast to generate an efficient return on assets?
Company
-18.44%
Industry
20.15%
NAUT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NAUT earnings per share forecast

What is NAUT's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.66
Avg 2 year Forecast
-$0.77
Avg 3 year Forecast
-$0.70

NAUT revenue forecast

What is NAUT's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$2.0M
Avg 2 year Forecast
$13.8M
Avg 3 year Forecast
$67.5M

NAUT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NAUT$3.85$10.33+168.39%Buy
ATRA$5.16$15.00+190.70%Buy
TNGX$5.41$20.67+282.01%Strong Buy
OCGN$2.24$6.50+190.18%Buy
HUMA$4.69$17.40+271.00%Strong Buy
View Top Biotech Stocks

NAUTILUS BIOTECHNOLOGY Stock Forecast FAQ

Is NAUTILUS BIOTECHNOLOGY Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: NAUT) stock is to Buy NAUT stock.

Out of 4 analysts, 1 (25%) are recommending NAUT as a Strong Buy, 1 (25%) are recommending NAUT as a Buy, 2 (50%) are recommending NAUT as a Hold, 0 (0%) are recommending NAUT as a Sell, and 0 (0%) are recommending NAUT as a Strong Sell.

What is NAUT's earnings growth forecast for 2022-2024?

(NASDAQ: NAUT) NAUTILUS BIOTECHNOLOGY's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.78%.

NAUTILUS BIOTECHNOLOGY's earnings in 2022 is -$57,669,000.On average, 2 Wall Street analysts forecast NAUT's earnings for 2022 to be -$82,144,691, with the lowest NAUT earnings forecast at -$87,123,157, and the highest NAUT earnings forecast at -$77,166,225. On average, 2 Wall Street analysts forecast NAUT's earnings for 2023 to be -$95,835,473, with the lowest NAUT earnings forecast at -$102,058,555, and the highest NAUT earnings forecast at -$89,612,390.

In 2024, NAUT is forecast to generate -$87,123,157 in earnings, with the lowest earnings forecast at -$87,123,157 and the highest earnings forecast at -$87,123,157.

What is NAUT's revenue growth forecast for 2022-2024?

(NASDAQ: NAUT) NAUTILUS BIOTECHNOLOGY's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 17.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.29%.

NAUTILUS BIOTECHNOLOGY's revenue in 2022 is $0.On average, 2 Wall Street analysts forecast NAUT's revenue for 2022 to be $242,700,223, with the lowest NAUT revenue forecast at $99,569,322, and the highest NAUT revenue forecast at $385,831,124. On average, 2 Wall Street analysts forecast NAUT's revenue for 2023 to be $1,721,304,661, with the lowest NAUT revenue forecast at $1,618,001,489, and the highest NAUT revenue forecast at $1,824,607,833.

In 2024, NAUT is forecast to generate $8,401,161,578 in revenue, with the lowest revenue forecast at $8,401,161,578 and the highest revenue forecast at $8,401,161,578.

What is NAUT's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: NAUT) forecast ROA is -18.44%, which is lower than the forecast US Biotechnology industry average of 20.15%.

What is NAUT's Price Target?

According to 3 Wall Street analysts that have issued a 1 year NAUT price target, the average NAUT price target is $10.33, with the highest NAUT stock price forecast at $13.00 and the lowest NAUT stock price forecast at $8.00.

On average, Wall Street analysts predict that NAUTILUS BIOTECHNOLOGY's share price could reach $10.33 by Jan 6, 2023. The average NAUTILUS BIOTECHNOLOGY stock price prediction forecasts a potential upside of 168.39% from the current NAUT share price of $3.85.

What is NAUT's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: NAUT) NAUTILUS BIOTECHNOLOGY's current Earnings Per Share (EPS) is -$0.57. On average, analysts forecast that NAUT's EPS will be -$0.66 for 2022, with the lowest EPS forecast at -$0.70, and the highest EPS forecast at -$0.62. On average, analysts forecast that NAUT's EPS will be -$0.77 for 2023, with the lowest EPS forecast at -$0.82, and the highest EPS forecast at -$0.72. In 2024, NAUT's EPS is forecast to hit -$0.70 (min: -$0.70, max: -$0.70).

What is NAUT's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: NAUT) forecast ROE is -20.29%, which is considered weak.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending StocksStock Market SectorsStock Market Industries
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.